Sponsors (52)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Authorizes and updates the National Breast and Cervical Cancer Early Detection Program to emphasize prevention, equity, and patient navigation, and adds an explicit funding authorization of $235 million per year for fiscal years 2026–2030. It revises program language and grantee requirements to focus services on evidence-based screening and diagnostic care, and directs the Government Accountability Office to report on program eligibility, trends, and barriers by September 30, 2027. The changes aim to increase access to screening and follow-up services—especially for higher-risk and underserved populations—while providing Congress and program managers updated data on who is served and what limits access to care.
The bill directs significant, multi-year federal funding and program changes to expand and standardize breast and cervical cancer screening for underserved women—improving early detection and equity—while increasing federal spending and imposing some limits on local flexibility, with a modest risk of overdiagnosis and no immediate guarantee that reported barriers will be remedied.
Women (especially low-income, uninsured, and underserved) will gain expanded access to breast and cervical cancer screening and diagnostic services through sustained program funding, increasing opportunities for earlier detection.
The bill authorizes $235 million per year (FY2026–2030) for the National Breast and Cervical Cancer Early Detection Program, enabling service expansion and more consistent program operations for providers and states.
Program outreach and patient navigation supports will improve access for geographically or culturally isolated women and help reduce disparities in cancer outcomes.
The bill increases federal spending (auth. $235M/year) which could raise budgetary pressure, require offsets elsewhere, or increase costs for taxpayers.
Expanding screening could lead to more follow-up procedures and potential overdiagnosis, causing anxiety and additional medical costs for some patients.
Requiring alignment with 'relevant evidence-based recommendations' may exclude certain local practices or newer approaches that lack national endorsement, limiting local flexibility and innovation in care delivery.
Introduced March 26, 2025 by Joseph Morelle · Last progress March 26, 2025